Credit Suisse’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $6.55M | Buy |
69,100
+729
| +1% | +$62.5K | 0.01% | 1153 |
|
|
2023
Q4 | $6.31M | Sell |
68,371
-986
| -1% | -$63.9K | 0.01% | 1200 |
|
|
2023
Q3 | $3.48M | Sell |
69,357
-6,122
| -8% | -$327K | ﹤0.01% | 1496 |
|
|
2023
Q2 | $4.77M | Buy |
75,479
+12,203
| +19% | +$663K | ﹤0.01% | 1371 |
|
|
2023
Q1 | $2.85M | Buy |
63,276
+3,726
| +6% | +$168K | ﹤0.01% | 1663 |
|
|
2022
Q4 | $2.61M | Buy |
59,550
+1,110
| +2% | +$53.2K | ﹤0.01% | 1730 |
|
|
2022
Q3 | $3.85M | Buy |
58,440
+2,819
| +5% | +$181K | ﹤0.01% | 1418 |
|
|
2022
Q2 | $2.81M | Sell |
55,621
-2,261
| -4% | -$132K | ﹤0.01% | 1672 |
|
|
2022
Q1 | $3.7M | Buy |
57,882
+5,363
| +10% | +$385K | ﹤0.01% | 1674 |
|
|
2021
Q4 | $5.63M | Sell |
52,519
-923
| -2% | -$96.5K | ﹤0.01% | 1925 |
|
|
2021
Q3 | $5.49M | Buy |
53,442
+4,452
| +9% | +$415K | ﹤0.01% | 1977 |
|
|
2021
Q2 | $4.31M | Sell |
48,990
-2,730
| -5% | -$250K | ﹤0.01% | 2207 |
|
|
2021
Q1 | $5.03M | Sell |
51,720
-30,968
| -37% | -$3.09M | ﹤0.01% | 2063 |
|
|
2020
Q4 | $9.27M | Buy |
82,688
+21,886
| +36% | +$2.31M | ﹤0.01% | 1630 |
|
|
2020
Q3 | $5.64M | Sell |
60,802
-17,327
| -22% | -$1.33M | ﹤0.01% | 1717 |
|
|
2020
Q2 | $6.09M | Buy |
78,129
+36,665
| +88% | +$2.48M | ﹤0.01% | 1584 |
|
|
2020
Q1 | $2.42M | Sell |
41,464
-98,308
| -70% | -$6.33M | ﹤0.01% | 2001 |
|
|
2019
Q4 | $11.2M | Buy |
139,772
+101,758
| +268% | +$7.62M | 0.01% | 1348 |
|
|
2019
Q3 | $2.79M | Buy |
38,014
+7,796
| +26% | +$674K | ﹤0.01% | 2220 |
|
|
2019
Q2 | $2.85M | Sell |
30,218
-11,637
| -28% | -$960K | ﹤0.01% | 2179 |
|
|
2019
Q1 | $3.35M | Sell |
41,855
-5,154
| -11% | -$381K | ﹤0.01% | 2005 |
|
|
2018
Q4 | $2.53M | Sell |
47,009
-4,399
| -9% | -$267K | ﹤0.01% | 2066 |
|
|
2018
Q3 | $4.01M | Buy |
51,408
+7,833
| +18% | +$544K | ﹤0.01% | 1844 |
|
|
2018
Q2 | $2.77M | Sell |
43,575
-5,740
| -12% | -$457K | ﹤0.01% | 2185 |
|
|
2018
Q1 | $4.52M | Buy |
49,315
+13,804
| +39% | +$1.19M | ﹤0.01% | 1776 |
|
|
2017
Q4 | $2.68M | Sell |
35,511
-10,707
| -23% | -$753K | ﹤0.01% | 2221 |
|
|
2017
Q3 | $3.22M | Buy |
46,218
+10,974
| +31% | +$586K | ﹤0.01% | 2145 |
|
|
2017
Q2 | $1.78M | Sell |
35,244
-4,801
| -12% | -$204K | ﹤0.01% | 2304 |
|
|
2017
Q1 | $1.6M | Buy |
40,045
+8,650
| +28% | +$310K | ﹤0.01% | 2514 |
|
|
2016
Q4 | $880K | Buy |
31,395
+11,725
| +60% | +$353K | ﹤0.01% | 3109 |
|
|
2016
Q3 | $584K | Sell |
19,670
-5,918
| -23% | -$147K | ﹤0.01% | 3341 |
|
|
2016
Q2 | $519K | Buy |
+25,588
| New | +$465K | ﹤0.01% | 3401 |
|
Other funds holding BPMC
RSCM
Credit Suisse's BPMC Position: Q1 2024 in Review
Credit Suisse increased its Blueprint Medicines (BPMC) stake by 1.1% in Q1 2024, buying an estimated $62.5K and bringing the position to 69,100 shares worth $6.55M. The position accounts for 0.01% of the portfolio, ranked #1153.
Credit Suisse first reported a position in BPMC in Q2 2016 and has held it in 32 quarters since. The position peaked at $11.2M in Q4 2019. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.
- Credit Suisse held 69,100 shares of Blueprint Medicines worth $6.55M as of Q1 2024.
- Credit Suisse bought 729 Blueprint Medicines shares in Q1 2024, an estimated $62.5K.
- Blueprint Medicines made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1153 holding.
- Credit Suisse first reported a position in Blueprint Medicines in Q2 2016 and has held it in 32 quarters since.
- Credit Suisse's Blueprint Medicines position peaked at $11.2M in Q4 2019.
- 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.